Biogen Inc. (BIIB) Is Climbing On Spinraza Data

10/5/2017 9:42 AM ET

Biogen Inc. (BIIB) announced Thursday morning that data shows that earlier initiation of treatment with SPINRAZA may improve motor function outcomes in infants and children with spinal muscular atrophy.

Biogen gapped open higher Thursday morning and has continued to rise in early trade. The stock is now up 10.99 at $325.91. Biogen has climbed to a 3-week high and is approaching the highs of the year, around $330 per share.